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The Search for Antithrombotic Therapy
H. C.  Hemker
There is no disease in the western world that
demands a higher toll in death and disability
then thrombotic disease. Coronary infarction,
stroke, circulation problems in the legs, ma,ny
cases of hypertension and scores of other dis-
eases are all members of one big family: athero-
sclerotic vessel disease. A11 these diseases tart
by microthrombosis at the inside of the vessel
wall and they usually end by either massive
occlusive thrombosis or bleeding.
If you would think thrombosis therefore
will be the main concern of medical research you
are mistaken ! Most people, even most doctors,
even indeed most cardiologists, are barely aware
of the important role of thrombosis as a mech-
anism of disease. This is readily seen if we have
a look at the research efforts in different fields.
If for every patient that dies from circulatory
disease in the Netherlands fl.500. is spent on
research, then fl. 3000.- is paid for every cancer
patient and fl. 15000.- for every AIDS patient.
For years and years even the research
efforts in the field of circulation have touched
the subject of thrombosis only lightly. Cardio-
logists have done marvellous work in plumbing
and electricity,that is to say in haemodynamics
and in electrophysiology. This has been very
useful in mending the damage brought about by
the obstruction of vessels but it left aside the
cause of the obstruction. Actually it is not until
very recently, with the advent of thrombolytic
therapy, that most cardiologists became aware
of the role of thrombosis in the diseases they so
frequently see.
I will not dwell upon the causes of this
strange situation. It is a fact however, that every
layman will tell you that unlimited cell growth is
the cause of cancer but many doctors will be
insecure about the role of vessel disease in the
mortality of our population.
Some of you, who have refrained from
eating eggs and fat meat for a number of years
will get uneasy now. Has it not been demon-
strated, they think, that cigarette smoking,
cholesterol, diabetes, lack of physical exercise
etc. are the cause ofatheriosclerosis rather than
thrombosis?
Indeed, epidemiological research has de-
fined a number of risk factors that correlate
with the occurence ofcoronary infarction. In a
sense one can say that smoking causes coronary
infarction and other circulatory problems.
People who do not smoke will get less than half
the trouble of those who do smoke. If I maintain
that thrombosis is at the basis of atherosclerotic
heart and vessel disease I mean to say that it is
the common pathogenetic in these diseases.
It is the old but always disturbing question
ofcorrelation and cause. There is an established
correlation between malarta and the bad air of
the marshlands. So good indeed that it served to
give the disease its name. There is a good
correlation between unhappy love and tuber-
culous consumption, or at least it was thought
to be observed. Still it was not until the falci-
parum malaria and its vector the mosquito were
discovered that a rational combat of malaria
could begin. It was not until tuberculosis was
recognized to be of bacterial origin that a
rational medical attack on this disease was
possible. In an analogous way we can say that
smoking indeed does cause vessel disease, but
that it does so via thrombosis.
It is high time that we should recognize that
thrombosis is the mechanism underlying vessel
disease and that research on thrombosis is the
only way to attack this scourge. This being said
you will not be amazed that the rest of my talk is
devoted to thrombosis.
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as coagulated blood such as we may observe it
when blood clots outside the body.
and it will cause flbrinogen from the blood
plasma to transform into fibrin flbers. In this
way a solid mass comes into being. If the wound
in the vessel wall is an exterior triuma then this
one case it is life-saving, in the other life_
threatening. This immediately shows one of theproblems of thrombosis therapy: it should beprevent thrombosis but leave haemostatis in_
Now who will find such a therapeutic for
thrombosis ? What type of research will lead to
new efficient antithrombotics ?
The three components of the thrombosis
mechanism, the platelet, the vessel wall and theplasma interact very closely indeed but the
people who study them usually do not. In the
laboratories of haemostasis and thrombosrs
attention. One may mention the studies onprostanoids by Vane and the culture of endo_
thelial cells by Jaffe.
cause.
The study of platelets, in more then 20years of research has essentially left us empty
handed as far as therapeutics 
-u.. 
"o.r"..n"d!Indeed. there is only one antiplatelet drug that
nas unequlvocally been shown to be effective inpreventtng coronary infarction: good old
Aspirin. Many other drugs are at the best as
active as Aspirin is, even though they inhibilplatelet f,unction in a number of different ways.
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therapy. Aspirin indeed does inhibit cyclooxy-
genase and thus thromboxane synthesis but
then it has not been proven that it is this action
of Aspirin that is responsible for its anti-
thrombotic effect.
If we are to plan a serious attack on
thrombotic disease I would be in favour of
basing ourselves of these data and recognize
that the only effective antithrombotic drugs are
anticoagulants. This means drugs that inhibit
the coagulation enzyme thrombin. Both oral
anticoagulants and heparin have a variety of
effects on other things than thrombin, so you
might reason that it may be one of the other
activities that is actually antithrombotic. I can-
not exclude this possibility but in defence of my
standpoint I can say that heparin on the one
hand and oral anticoagulants on the other are so
different that the only effect that we know them
to have in common is their effect on blood
coagulation. We are left of course with Aspirin
to which I shall come back later.
Oral anticoagulants and heparins are also
very different in the way of their action on the
coagulation mechanism. Oral anticoagulants
are antagonists of vitamin K. Vitamin K is
necessary for the synthesis of certain coagula-
tion factors. When there is no vitamin K then
there will be a lack of coagulation factors,
among which prothrombin, and the thrombin
formation in clotting blood will be diminished.
In fact I discovered in 1963 that under these
circumstances prothrombin is present but in a
modified and unactive form. Later this led to the
discovery of the mode of action of vitamin K
and the role of certain modified aminoacid
residues in blood. This helped in establishing the
correct way of executing the treatment but it
does not change the view that, under oral
anticoagulation for all practical purposes pro-
thrombin is diminished. Recent results from our
laboratory suggest hat only the diminution of
prothrombin influences the clotting process in
oral anticoagulation.
Heparin acts very differently from oral
anticoagulants. Recentlywe could show that the
action of classical heparin in plasma is based on
one phenomenon only: the fact that it makes
thrombin disappear more quickly. The only
thing that oral anticoagulants and heparin have
in common therefore is their action on the
amount of thrombin that is formed in clotting
plasma. We recently did a thorough study on the
newly developed low molecular weight hepa-
rins. These promise to have many advantages
compared to classical heparin but they still act
on thrombin or its formation.
This is the basis for my conviction that
thrombin is the final common pathway of all
types of thrombosis. The attack on thrombosis
should therefore be an attack on thrombin.
This may not seem very revolutionary to
the non-specialist but you must be aware that in
the last twenty years the leading paradigma has
been that the most killing type of thrombosis,
arterial thrombosis, is essentially a platelet
disease. Therefore, the search for new anti-
thrombotics in the last 20 years has been
primarily a search for antiplatelet drugs and I
propose that this may have been the wrong
approach.
What may have been the reasons for the
prime importance attributed to platelet aggre-
gation? I can see two: one is the concept of the
essential difference between arterial and venous
thrombosis, the other is the innate opportuntsm
of the research scientist who is fascinated by a
new technique.
Every pathologist can tell you about the
difference between the white and the red throm-
bus and usually he will oppose them as if the
Russian revolution still raged in our blood-
streams. The white thrombus consists mainly of
blood platelets sticking to each other and to the
collagen of the vessel wall. They are held
together by fibrin threads but apart from that
there is few evidence ofblood coagulation. The
white thrombus is the one found in the arterial
system, the plug that causes infarction and
stroke. The red thrombus in the classical de-
scription is hardly different from clotted blood.
It consists of a fibrin mesh in which the cellular
elements of the blood are caught. Erythrocytes
are abundant, hence its red colour. Would it not
be logical then to attack the white , that is to
say the platelet thrombus, with antiplatelet drugs
and the red one with anticoagulant therapy?
More important still: Anticoagulant thera-
py proved very effective against red, venous
thrombi but for a long time it was much more
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difficult to prevent afteial thrombosis in that
way. It thus seemed logical to attack the platelet
first.
As to the second reason, you can imagine
how enthusiastic the researchers became when
Born announced his simple method for the
study of platelet aggregation. They immediately
seized the occasion to have a direct look at the
process that made platelet thrombi. Antiplatelet
drugs became synonymous with aggregation
inhibitors and lots of them were found. It came
as an unpleasant surprise that many of these
drugs that perfectly inhibited platelet aggre-
gation in practice still would not make very
good antithrombotics. In my opinion this is
because aggregation is not the adequate model
for the arterial thrombus.
I feel that the microscopical structure of the
white thrombus as seen by the pathologist,
together with the fascination ofthe discovery of
Born have made the scientific world jump to the
conclusion that aggregation would be the in
vitro representation of arterial thrombosis and
that good aggregation inhibitors would make
good antithrombotics. This is not true.
Sometimes they make reasonable antithrom-
botics, like Aspirin, sometimes perfect aggre-
gation inhibitors make bad antithrombotics,
like PGE 1.
On the other hand it appeared that oraL
anticoagulation, when applied steadily and
deeply was not as bad as that in preventing
afterial thrombosis. This has been conclusively
shown by the trials conducted by Loeliger and
his collegues in Leiden. Also in the earliest
stages of the formation of a haemostatic plug as
well as in the earliest stages of the formation of
an arterial thrombus, fibrin can be observed
almost immediately. From this one can deduct
that thrombin must be there already at the
moment that platelets aggregate to any appreci-
able extent. In fact, it is probably thrombin that
makes the platelets aggregate. That thrombin
plays such an important role in phenomena
that, morphologically, seem to be dominated by
platelets needs not surprise us. Thrombin is
known to be the most potent physiological
platelet activating agent. It is active at concen-
trations that are one or more orders of magni-
tude higher than ADP, adrenalin and every
other possible platelet activator.
This last observation points to the direc-
tion in which we will have to search for new
antithrombotics. It is rather the cooperation
between platelets and the thrombin forming
mechanism that should be our point of attack
than either the platelet or the clotting system
alone. Some of our recent experimental results
illustrate this point.
We investigated the development of throm-
bin in platelet rich plasma and compared it to
platelet poor plasma. ln PPP in the course of
20 min hardly any thrombin develops. In PRP
however, after 10-I2min there is a sudden burst
of thrombin formation. This is because very
small amounts of thrombin activate the plate-
lets. The activated platelets then, in their turn,
trigger an outburst of thrombin formation. This
immediately demonstrates that it is silly to think
that thrombin formation and platelet activation
are isolated phenomena. One should recognize
that they are tightly coupled in a positive
feedback loop. As soon as platelets and plasma
are both present they interact. This becomes
even more evident if we try to imitate the effect
of tissue wounding by adding tiny amounts of
thromboplastin to the system. Added in such a
high dilution that in PPP no increase of throm-
bin formation can be seen, it will still have a
marked effect in PRP. It will cause the burst of
thrombin formation to occur about 4 min
earlier than in absence of thromboplastin. This
means that minute cell damage will promote
thrombin generation in PRP even though it wih
have no influence on PPP. At higher concentra-
tions of thromboplastin the difference between
PRP and PPP become less important, so that in
the usual laboratory tests, like the PT, the effect
of platelets will be hardly observable.
We see that the effects of small amounts of
tissue thromboplastin are only observed if both
plasma and platelets are present. I think that
coagulation in presence of low concentrations
of thromboplastin in platelet rich plasma may
be a more realistic model of the in vivo situation
than isolated platelet or isolated plasma alone,
were it only because the three components that
are due to encounter in in vivo thrombus
formation are present here.
We investigated the effect of antithrom-
botic drugs in this system. It appeared that the
three recognized therapeutics of thrombosis all
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postponed the explosion of thrombin in PRP
whereas other substances like PGE 1, Ihat can
completely inhibit aggregation but that have
hardly any effect of thrombosis, do not in-
fluence the cooperation between platelets and
plasma.
These results make us surmise that this
cooperative effect might be a good indicator of
antithrombotic actions, a good screening test
for antithrombotic drugs.
Now there are two possibilites, either this is
trnre or it is not. If it is true than we have
obtained a comparatively easy way to find new
antithrombotics, no matter whether they act
primarily on platelets, like Aspirin, or on the
clotting system, like the various heparins and
heparin-like drugs. It is equally possible, how-
ever, that our approach after all will not lead to
the development of new drugs. Then the investi-
gation will not lead to the development of new
drugs. Then the investigation of the novel
cooperative effect between blood coagulation
and platelets will anyhow increase our know-
ledge and thus may indirectly contribute to the
development of better thrombosis treatment.
For the next few years it seems that the
daily practice of thrombosis treatment will have
to do with carefully standardized oral anti-
coagulation and with low molecular weight
heparins. In the near future other thrombin
generation inhibitors may be expected to be
developed. Antiplatelet drugs that specifically
inhibit the procoagulant activity of blood plate-
lets may be among the more promising ones.
Zusammenfassung
Thrombotische Erkrankungen fordern in der
westlichen Welt den hochsten Zoll an Toten und
fiihren zu verbreiteter Invaliditiit. Mikrothrom-
bose an der GefdBinnenwand ist Anfang und
Ursache fast aller Infarkte, Apoplexien, Durch-
blutungsstorungen, Hochdruckerkrankungen.
Und doch: weder nach Umfang noch Intensitdt
wird der entsprechende Forschungsaufwand
dieser Tatsache gerecht. Wir setzen in Holland
pro Patient bei Kreislauferkrankungen nur 500
Gulden an Forschungsmitteln ein, bei Krebs
aber 3000 und bei AIDS sosar 15000.
In der Tat: Das Wissen iiber die Throm-
bose ist wenig verbreitet, und erst die thrombo-
lytische Therapie hat auch die Kardiologen auf
ihre Bedeutung aufmerksam werden lassen.
Immer noch hiilt der Laie - und gewiB nicht
ohne Grund! Rauchen, hohen Cholesterin-
spiegel, Diabetes, Bewegungsmangel frir die
Ursachen von Arteriosklerose; er denkt nicht
primdr an Thrombose. Fiir mich aber steht fest:
Thrombose liegt allen arteriosklerotischen Herz-
und GefdBerkrankungen zugrunde. Die Erfor-
schung der Thrombose ist damit der Weg zur
Bekdmpfung dieser Krankheiten.
Was ist Thrombose? Bei ihrer Entstehung
wirken drei Faktoren zusammen: GefdBwand,
Blutpliittchen, Blutplasma. Gef,iBwandschiidi-
gungen setzen riber Thromboplastin und Plas-
maprotein (F VID einen ProzeB in Gang, der bei
duBeren Verletzungen zur Bildung des lebens-
rettenden, bei Arteriosklerose zum Entstehen
des lebensgefdhrdenden hdmostatischen Pfrop-
fens frihrt. Damit wird ein zentrales Problem der
Therapie deutlich: sie muB der Thrombose
vorbeugen, ohne die Blutgerinnung auszuschal-
ten.
. 
Die drei Komponenten GefdBwand, Blut-
pldttchen, Blutplasma wirken in fataler Perfek-
tion zusammen, viel besser als die Spezialisten,
die sie untersuchen: die Koagulationsforscher,
die Blutpliittchenspezialisten, die Gefd8wand-
experten. Bessere Integration ist wichtig. Die
Antigerinnungsmittel sind wirksam, aber auch
gefiihrlich. Aspirin hat sich gut gegen Pldttchen-
konglomerate bewdhrt. Bei der Gef,dBwandfor-
schung registrieren wir noch keinen therapeuti-
schen Durchbruch.
Meine Forschunsen und Erfahrunsen ha-
ben mich zu derllber"zeugung geltihrt: ihtorn-
bin ist der Schliissel zur Thrombose. Wer
Thrombose bekdmpfen will, muB das Thrombin
bekiimpfen. Das sage ich vor allem im Blick
darauf, daB man in den letzten 20 Jahren beim
todlichsten Typ der Thrombose, der arteriellen,
die Konglomeration der Blutpliittchen fiir ent-
scheidend hielt. Das war - meine ich - ein
Fehlansatz, der wohl mit auf der konventionel-
len Unterscheidung zwischen ,,weiBer" und
..roter" Thrombose beruhte.
Aber Plattchenaggregation - Borns For-
schunsen waren hier bahnbrechend ist wohl
The Search  fo r  Ant i th rombot ic  Therapv / l
doch nicht das Entscheidende bei arterieller
Thrombose. Es stimmt nicht, daB wir im Aggre-
gationsprozeB der Pl2ittchen, wie wir ihn in vitro
konstruieren, den Ablauf einer arteriellen
Thrombose in vivo sehen. Auch gute Aggrega-
tionshemmer schritzen keineswegs zuverldssig
vor Thrombose.
Wahrscheinlich fiihrt ndmlich das Throm-
bin zur Pldttchenkonglomeration. Thrombin ist
der stdrkste Wirkungsfaktor bei der Aktivie-
rung der Blutpldttchen. Hier miissen wir anset-
zen. Unsere Versuche haben gezeigt, wie eng die
Pliittchendichte im Plasma und das schubartige
Auftreten von Thrombin zusammenhdngen.
Auch kleinste GefdBwandverletzungen wirken
ribrigens steigernd in dieser Richtung.
Wenn unsere Beobachtungen und die aus
ihnen folgenden therapeutischen Ansdtze stim-
men, wird es moglich sein, neue antithromboti-
sche Mittel zu entwickeln, die vor allem auf das
Thrombin zielen. Nattirlich schlieBt ihr Einsatz
die Anwendung und Weiterentwicklung von
sorgf,dltig abgestimmten gerinnungshemmen-
den Mitteln, Heparinen mit niederem Moleku-
largewicht und Antikoagulantien im Pldttchen-
bereich nicht aus.
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